Literature DB >> 10873042

Nonrhabdomyosarcoma soft tissue sarcomas in children: is age at diagnosis an important variable?

A A Hayes-Jordan1, S L Spunt, C A Poquette, A M Cain, B N Rao, A S Pappo, S J Shochat.   

Abstract

PURPOSE: The associations between age at diagnosis, tumor characteristics, and outcome in children diagnosed with nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) were studied.
METHODS: Retrospective review was conducted of 192 children from 1962 through 1996. Patients were divided into groups: birth to 1 year (n = 13), 1 to 5 years (n = 26), 5 to 10 years (n = 49), 10 to 15 years (n = 55), and older than 15 years (n = 49) of age at diagnosis. Characteristics including IRS group, histological grade and pattern, tumor size, and invasiveness were investigated. Survival rate was estimated by age group. The median follow-up was 8.8 years (range, 2 to 28 years).
RESULTS: There were 81 group I patients, 40 group II, 41 group III, and 30 group IV. A significant difference of IRS groups among the age groups was seen (P = .034). There were no IRS group IV patients less than 1 year of age; 50% of IRS group IV patients were older than 15 years. A significant difference in the distribution of histological grade among the age groups (P = .032) was seen. Ten of 13 (77%) children less than 1 year of age had low-grade tumors, whereas 42%, 45%, 60%, and 37% of patients aged 1 to 5, 5 to 10, 10 to 15, and older than 15 years, respectively, had low-grade tumors. Patients older than 15 years had the highest incidence of invasive tumors (59%). Histological pattern also varied with age. The most prevalent histology in the less-than-1-year age group was infantile fibrosarcoma. No predominant histology was seen in the 1- to 5-year age group. Malignant fibrous histiocytoma was the most frequent histological subtype in children between 5 and 10 years of age. In the 10- to 15-year age group and children older than 15 years the malignant peripheral nerve sheath tumor and synovial sarcoma were the most prevalent subtypes. Without adjusting for any other factors, age group was prognostic of survival (P = .007). Patients less than 1 year at diagnosis had the best outcome, with a 5-year survival rate of 92% +/- 9%. Five-year estimates were lowest for patients older than 15 years (49% +/- 7%).
CONCLUSIONS: Significant differences in IRS group, histological grade, and histological subtype were observed in different age groups. Infants with NRSTS were more likely to have low grade, less invasive, and lower stage tumors. These characteristics may account for their improved prognosis.

Entities:  

Mesh:

Year:  2000        PMID: 10873042     DOI: 10.1053/jpsu.2000.6934

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  7 in total

1.  Conditional survival of pediatric, adolescent, and young adult soft tissue sarcoma and bone tumor patients.

Authors:  Judy Y Ou; Holly Spraker-Perlman; Andrew C Dietz; Rochelle R Smits-Seemann; Sapna Kaul; Anne C Kirchhoff
Journal:  Cancer Epidemiol       Date:  2017-10-07       Impact factor: 2.984

2.  Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database.

Authors:  Andrea Ferrari; Iyad Sultan; Tseng Tien Huang; Carlos Rodriguez-Galindo; Ahmad Shehadeh; Cristina Meazza; Kirsten K Ness; Michela Casanova; Sheri L Spunt
Journal:  Pediatr Blood Cancer       Date:  2011-07-25       Impact factor: 3.167

3.  Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups.

Authors:  Andrea Ferrari; Rosalba Miceli; Annie Rey; Odile Oberlin; Daniel Orbach; Bernadette Brennan; Luigi Mariani; Modesto Carli; Gianni Bisogno; Giovanni Cecchetto; Gian Luca De Salvo; Michela Casanova; Max M Vannoesel; Anna Kelsey; Michael C Stevens; Meenakshi Devidas; Alberto S Pappo; Sheri L Spunt
Journal:  Eur J Cancer       Date:  2010-12-08       Impact factor: 9.162

4.  Margin status and multimodal therapy in infantile fibrosarcoma.

Authors:  Jason P Sulkowski; Mehul V Raval; Marybeth Browne
Journal:  Pediatr Surg Int       Date:  2013-06-14       Impact factor: 1.827

5.  Pediatric soft tissue sarcoma of the limbs: clinical outcome of 97 patients.

Authors:  Andrea Sambri; Giuseppe Bianchi; Ilaria Cucurnia; Marco Gambarotti; Davide Maria Donati
Journal:  Eur J Orthop Surg Traumatol       Date:  2017-08-01

6.  Resectable pediatric nonrhabdomyosarcoma soft tissue sarcoma: which patients benefit from adjuvant radiation therapy and how much?

Authors:  Lynn Million; Sarah S Donaldson
Journal:  ISRN Oncol       Date:  2012-03-15

7.  The effect of adjuvant therapies on long-term outcome for primary resected synovial sarcoma in a series of mainly children and adolescents.

Authors:  Monika Scheer; Christian Vokuhl; Sebastian Bauer; Jörg Fuchs; Steffan Loff; Beate Timmermann; Marc Münter; Anton George Henssen; Bernarda Kazanowska; Felix Niggli; Ruth Ladenstein; Gustaf Ljungman; Ewa Koscielniak; Thomas Klingebiel
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-17       Impact factor: 4.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.